News

By Daniella Parra Glucotrack, Inc. (Nasdaq: GCTK) said it has submitted an Investigational Device Exemption application to the FDA to begin a U.S. clinical study for its fully implantable continuous blood glucose monitoring technology. The company said it is designed to deliver real-time glucose readings without the need for an external wearable device. “Submission of […]

Waleed Hassanein: Thank you so much, Hannah. As always, joining me today is Gerardo Hernandez, our Chief Financial Officer. Since inception, TransMedics has been relentless in our pursuit to transform organ transplant therapy by increasing utilization of donor organs and improving the clinical outcomes of transplant patients throughout -- through technology and service innovation and by disrupting the status quo.

AMD upgraded, Reddit downgraded: Wall Street's top analyst calls

Moby summary of TransMedics Group, Inc.'s Q1 2026 earnings call

TransMedics Group (NASDAQ:TMDX) reported first-quarter 2026 revenue of $174 million, up about 21% year over year and 8% sequentially, as the company continued to expand adoption of its Organ Care System (OCS) platform and its National OCS Program (NOP) logistics model while increasing investment in

While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

TransMedics Group unveiled its Controlled Hypothermic Organ Preservation System, or CHOPS, a new active cooling device for donor organ storage. The company outlined plans for CHOPS to serve as the control arm in the ENHANCE Heart Part B and DENOVO Lung clinical trials. These updates add a new organ preservation platform alongside TransMedics Group's existing transplant technology programs. TransMedics Group (NasdaqGM:TMDX) is drawing attention with CHOPS at a time when its share price...